Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B). European MCL Network.
|
Investigador Principal |
Dra. Eva Giné |
|
Estado del Protocolo |
Abierto en reclutamiento |
